Biophysical assessment of DC iontophoresis and current density on transdermal permeation of methotrexate

Rachna Prasad1,2, Sneh Anand1,2, Veena Koul1,2
1Centre for Biomedical Engineering, Indian Institute of Technology, Hauz Khas, 2Biomedical Engineering Unit, All India Institute of Medical Sciences, New Delhi, India

Abstract

Introduction: The effect of DC iontophoresis using low (0.2 mA/cm2) and high current density (0.5 mA/cm2) on transdermal permeation of methotrexate loaded into polyacrylamide hydrogel patch was investigated. Results: Flux of 20.57 ± 1.02 μg/cm²/h and 36.8 ± 2.21 μg/cm²/h was achieved with low and high current density DC iontophoresis, respectively. Attenuated total reflectance-Fourier Transform infrared (ATR-FTIR) spectra and microscopic studies of the treated skin samples supported the permeation results. A greater decrease in the peak height of asymmetric, symmetric C-H stretching vibration and ester peak was noticed with 0.5 mA/cm² current density as compared to 0.2 mA/cm² current density samples. Furthermore, an increase in the ratio of amide I and amide II bands from 2.6 to 11 with increase in current density was noticed, thus indicating that hydration levels are associated with iontophoresis and play an important role in increasing the drug permeation. Scanning electron microscopy revealed increase in pore size of the hair follicles. Light microscopy studies of the skin samples treated with low current density DC iontophoresis demonstrated epidermal thinning and focal disruptions, spongiosis and appendageal dilatations. With higher current density, disruption of epidermis in almost half of the sectioned area, loss of appendages and fractured collagen in the dermis was noticed. Moreover, the reversibility studies conducted in vivo on mice revealed that the recovery process had started within 24 h and is complete in 48 h for lower current density treated animals. However, the histological changes associated with 0.5 mA/cm² current density were not reversible in 48 h and edema, appendageal dilatations along with focal disruption of epidermis persisted. Conclusion: Hence our study suggests that high density current is not well-tolerated by the skin.

Key words: ATR-FTIR, current density, DC iontophoresis, methotrexate, skin histopathology

INTRODUCTION

Transdermal drug delivery is a noninvasive route of drug administration into the body through the skin. It offers many advantages over other routes of conventional drug delivery. However, only a few drug candidates have been successfully developed into suitable transdermal formulations because of the formidable skin barrier. The highly lipophilic nature of the skin restricts the permeation of hydrophilic, high molecular weight and charged compounds through the stratum corneum into the systemic circulation. Therefore, different chemical and physical methods for permeation enhancement have been used.

Transdermal iontophoresis is defined as application of an electrical potential that maintains a constant electric current across the skin and enhances the delivery of ionized as well as unionized molecules. It uses an electrode of the same polarity as the charge on the drug to drive ionic drug molecules into the body. The mechanisms of transdermal iontophoresis include electrorepulsion (a charged ion is repelled from an electrode with the same charge), electro-osmosis (convective flow of solvent through a charged pore that occurs in response to the preferential passage of counter ions when the electric field is applied), and current-induced skin permeability increment. One of the major advantages of iontophoretic drug delivery is the ability to readily and precisely control the drug-delivery profile through modulating the current output.

Methotrexate (MTX) is an antineoplastic agent used for the treatment of cancer, psoriasis and rheumatoid arthritis. MTX inhibits the enzyme dihydrofolate reductase thus inhibiting DNA synthesis. At high doses it is used for the treatment of cancer and at low doses, it has immunosuppressive and anti-inflammatory properties and is used for the treatment of psoriasis...
and rheumatoid arthritis. Various topical forms like ointments, creams and gels have been tried as the systemic use of this drug causes many side effects mainly, hepatic toxicity and liver damage but are still not available commercially.

The drug can be delivered either in solution formulation or through loading on to the hydrogel patches. Incorporation of the drug into hydrogels facilitates drug handling and release and in case of iontophoretic delivery, allows the patient to remain ambulant. It has been reported that the iontophoretic delivery of MTX from hydrogels was more effective than passive delivery from aqueous solution. It has been demonstrated that iontophoresis remarkably improved the transdermal delivery of MTX over passive diffusion. More interestingly, a case of palmer psoriasis treated with iontophoresis of MTX has been reported using current density for iontophoresis beyond the clinically acceptable limits. Although, the results with iontophoresis are promising, none of the papers give a detailed comparison between high and low current density used for iontophoresis.

The aim of the present study was to analyze the effects of current density on MTX permeation as well as to assess the skin injury caused by the above-mentioned physical enhancer by histological examination. Moreover, the reversibility of skin injury was studied in vivo.

MATERIALS AND METHODS

Reagents
MTX was a gift sample from Dabur (India), Acrylamide was obtained from Spectrochem Pvt. Ltd. (India), N, N-Methylene bis-acrylamide, potassium chloride and potassium dihydrogen phosphate from Sisco Research Laboratory (India), sodium chloride from E. Merck India Ltd. (India), dihydrogen-o-phosphate anhydrous from Qualikems fine chemicals Pvt. Ltd. (India), sodium hydroxide and ethyl acetate from Excelar Qualigens fine chemicals (India), ammonium persulphate from Thomas Baker chemicals Ltd. (India) and sodium metabisulphite from S.D. fine chemicals (India). Deionised water having a resistivity of 18 MΩ or greater was used to prepare all solutions and buffers.

MTX hydrogels
The hydrogel patches were synthesized using acrylamide monomer by solution polymerization method as described by Prasad et al., 2007.

Skin preparation and in vitro permeation studies from MTX hydrogels
All experiments were conducted according to the protocol approved by the Institutional Animal Ethics Committee (IAEC) of All India Institute of Medical Sciences, New Delhi, India. White albino mice (n=5 in each group) were procured from AIIMS and sacrificed. The hair was removed from the abdominal region using an animal hair clipper and the full-thickness skin was excised. Fat adhering to the dermis side was cleaned by using a blunt scalpel and isopropyl alcohol, taking care not to damage the skin. Finally, the skin was washed in tap water and observed physically for any gross damage. The fresh skin was used, for in vitro, attenuated total reflectance-Fourier transform infrared (ATR-FTIR) and histopathological studies.

For permeation studies, the mice skin was clamped between the two half-cells of the modified vertical Franz diffusion cell with epidermis facing the donor chamber and the area available for permeation was 5.72 cm². The skin was equilibrated for 1 h in phosphate buffer saline (pH 7.4) in the receptor chamber and was magnetically stirred throughout the experiment.

MTX-loaded patch was placed over the skin and DC iontophoresis using current density of 0.2 mA/cm² was applied for 1 h to the hydrogel patch through silver-silver chloride electrode and having same dimensions as the hydrogel patch to study the effect of low current density iontophoresis. Similarly the effect of high current density 0.5 mA/cm² was also studied. The experiments were done at thermostatically maintained temperature (37±2°C).

Quantification of MTX, data treatment, statistical analysis and polynomial curve fitting
For MTX quantification in receptor solution, 0.5-ml samples were withdrawn at specified intervals from the receiver compartment and analyzed for the amount of drug by UV-vis spectrophotometer (CARY 100 model) at 302 nm. The samples were also analyzed by HPLC using Waters 1525 binary pump attached to UV detector.

The cumulative amount of MTX permeated per unit skin surface area was plotted against time and Flux (J) was calculated as:

$$J = \frac{(dc/dt) V}{A}$$

where V=volume of solution in the receptor compartment of the diffusion cell, A=area of the patch, and dc/dt=change in concentration of drug in the receptor compartment solution of the diffusion cell with time. The percent enhancement in flux was calculated as follows:

$$\% \text{ enhancement in flux} = \left\{ \frac{\text{Flux with enhancer} - \text{passive flux}}{\text{passive flux}} \right\} \times 100$$

All experiments were repeated five times and the values are expressed as mean ± S.D. Statistical comparisons were made using Student’s t-test and the significance level was set at P<0.05.

For curve fitting, a third order polynomial expression, $Y = At^3 + Br^2 + Ct + D$, where $Y =$ total amount and $t =$ time, was utilized for a best curve fit to compare the rate of iontophoretic permeation of methotrexate with passive. The R-squared value was obtained for each curve.
C-H stretching, C=O stretching and amide peak absorbances were measured for each sample.

**Morphological evaluation by scanning electron microscopy**
The albino mice skin was treated with iontophoresis for 1 h and fixed in EM fluid. After fixing the samples for 48 h, they were washed with phosphate buffer saline and dehydrated using a graded series of ethanol solutions and finally dipped in acetone. The samples were air dried and mounted on the base plate and then coated with silver using vapor deposition technique. The surface of the skin sample was investigated using Cambridge Stereoscan model S4-10, scanning electron microscope.

**Histological examination by light microscopy**
The iontophoresis-treated skin area (both in vitro and in vivo) was excised after 1 h to study the effect on skin and after 24 h and 48 h in vivo to see the reversal of injury after enhancer application. The excised skin was fixed in 10% formalin and then subjected to processing for histological examination by light microscope. The skin samples were dehydrated by a series of graded ethanol then treated with xylene and finally embedded in paraffin blocks. Skin sections of 5-μm thickness were cut and stained with hematoxylin-eosin (H&E) stain. The mounting of the stained sections was done in DPX and observed under light microscope using a modified score (Table 1 for in vitro scoring).

**RESULTS AND DISCUSSION**

**Effect of current density on permeation**
The flux obtained with DC iontophoresis using 0.2 and 0.5 mA/cm² current density was 20.57±1.02 μg/cm²/h and 36.8±2.21 μg/cm²/h, respectively (P<0.05). It was observed that MTX permeation increased with increasing current density. Similar results have been obtained by Cesares-Delgadillo, 2010,[29] although they have tried different current densities for a different drug.

**Polynomial curve fitting**
A third order polynomial was chosen to model the experimental results as the data could not be presented by a quadratic. There was no significant improvement in the least square error by using a higher order polynomial, hence was not used for analysis. The results are presented in Figure 1 which shows the effect of DC iontophoresis on the net permeation of methotrexate at a given time calculated by third order polynomial curve fitting. A good correlation between experimental and polynomial simulation was obtained from the curve (R² >0.9). It can be observed from the curve that with the passive experiments (drug-loaded hydrogel patch), initially there is an increase in permeation, then there is decline and steady state is obtained. The drug diffusion is via the least resistant pathway, which reaches a saturation, so there is fall in permeation. Moreover, the swelling pattern of the hydrogel (0.4 mole%) is Fickian in nature (data not shown), which further supports that diffusion is the main mechanism of drug release.

Enhancement of permeation is required to achieve the desired drug levels.[18] From the curve, it can be seen that there is sharp rise in permeation with iontophoresis and then steady level is reached [Figure 1]. The ATR-FTIR and microscopic studies presented below also support this phenomenon.
ATR-FTIR studies
ATR-FTIR spectra of skin sample treated with current of 0.2 mA/cm² current density showed all the major peaks of the lipid and protein but with reduced intensity as compared to the control. A decrease of 28.12% and 31.25% in the peak height of asymmetric and symmetric C-H stretching vibration, respectively, as compared to the control, and 37.5% reduction in the ester peak was noticed [Table 2]. Furthermore, a decrease of 31.4% and 47.05% was noticed with amide I and amide II, respectively. With 0.5 mA/cm² current density iontophoretic samples, a greater reduction of 96.8%, 93.75% and 93.7% [Table 2] in asymmetric and symmetric C-H stretching and C=O stretching vibration, respectively, was obtained which was attributed to substantial amount of lipid extraction in the lipid protein domains. Moreover, an increase in the ratio of amide I and amide II bands from 2.6 to 11 with increase in current density from 0.2 to 0.5 mA/cm² was noticed, thus indicating that the hydration levels are associated with iontophoresis and play an important role in increasing the drug permeation.

The spectra also demonstrated a split in amide II band into 1553 cm⁻¹ and 1541 cm⁻¹. The split could be due to the disruption in hydrogen bonding associated with the head of ceramides, breaking interlamellar hydrogen bonding of lipid bilayer and disrupting barrier property of SC, resulting in loosening of lipid-protein domains thus allowing higher flux as compared to the passive treatment.

Scanning electron microscopy
The scanning electron micrographs of DC iontophoresis clearly showed increase in the pore size of the hair follicles [Figure 2]. This supports the involvement of shunt pathways for drug permeation during iontophoresis.[30,31] Kajimoto et al., 2011[32] have also reported the use of follicular pathways during iontophoresis.

Histopathological studies
Figure 3 depicts a comparison between control, DC (0.2 mA/cm²) and DC (0.5 mA/cm²). From the histopathological studies it is clear that at higher current density, 0.5 mA/cm², disruption of epidermis in almost half of the sectioned area was noticed [Figure 3b]. There was thinning of epidermis and spongiosis giving an epidermal score of 29. There was severe dermal edema with marked dilatation and loss of appendages and fractured collagen with a dermal score of 18. The dermal changes were higher as compared to iontophoresis with 0.2 mA/cm² current density.

Iontophoresis using lower current density of 0.2 mA/cm² showed focal disruptions of epidermis (less than ¼ of sectioned area) and bullae formation [Figure 3c] and an epidermal score of 24 was obtained. The dermis showed fractured collagen with moderated edema and mild appendageal damage, thus a dermal score of 12 was obtained. DC (0.5 mA/cm²) resulted in THS of 47 whereas at 0.2 mA/cm² DC, THS of 36 was observed indicating lesser skin injury.

The severe edema formation is evident as the hydration effects of iontophoresis are responsible for enhanced permeation of the drug. This has been depicted by the ratio of amide I/II band in ATR-FTIR spectroscopy described previously. Application of current reduces the resistance of skin and the decreased resistance is reflected in the increased permeability of the skin and therefore increased flux. Current causes epidermal destruction as well as appendageal damage, as we could see in all the histological slides as well as from scanning electron microscopy, therefore shunt pathway for drug permeation become more operative on current application.[30-32] To summarize, with 0.5 mA/cm² current density, damage was higher as compared to 0.2 mA/cm², which was in correlation with the flux observed. The higher current density provides more electromotive force that increases the flux. In vivo results in mice show that the damages associated with 0.5 mA/cm² current density were not reversible in 48 hours [Figure 4].

Reversibility studies (in vivo)
Reversibility studies were conducted in vivo after 24 and 48 h of the application of iontophoresis. It was observed that recovery process had started in 24 h and almost total recovery of epidermal as well as dermal changes was found in 48 h with low current density DC iontophoresis, however with iontophoresis using 0.5 mA/cm² current density, edema along with focal disruption of the epidermis persisted [Figure 4]. The partial

| Table 2: Percentage decrease in peak height for lipids and protein absorption bands after current treatment for 1h |
|---------------------------------------------------------------|
| Asymmetric C-H | Shift | % | Symmetric C-H | % | Ester C=O | % |
|----------------|------|---|---------------|---|-----------|---|
| Control        | 2920 | - | -             | 2852 | -         | 1743 |
| 0.2 mA/cm²     | 2923 | 3 | 28.12         | 2852 | 31.25     | 1744 |
| 0.5 mA/cm²     | 2928 | 8 | 96.8          | 2852 | 93.75     | 1744 |
denudation of the epidermis with left over basal layer showed a rapid recovery as compared to areas with loss of basal layers as seen with 0.5 mA/cm² current density iontophoresis.

CONCLUSIONS

It was observed that the transdermal permeation increased with increase in injury caused to the tissue. The higher current density (0.5 mA/cm²) increased the MTX flux tremendously, but the reversibility studies did not confirm its skin tolerance as the histological changes were not reversible in 48 h.

ACKNOWLEDGMENT

The authors are thankful to Dabur Research Foundation (India) for providing the gift sample of methotrexate.

REFERENCES

1. Kim YC, Park JH, Ludovice PJ, Prausnitz MR. Synergistic enhancement of skin permeability by N-lauroylsarcosine and ethanol. Int J Pharm 2008;352:129-38.
2. Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res 1996;13:1765-9.
3. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004;3:115-24.
4. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-18.
5. Asbill CS, El-Kattan AF, Michniak B. Enhancement of transdermal drug delivery: Chemical and physical approaches. Crit Rev Ther Drug Carrier Syst 2000;17:621-58.
6. Liu W, Hu M, Liu WS, Xue C, Xu H, Yang X. Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int J Pharm 2008;364:135-41.
7. Tezel A, Sens A, Tuchscherer J, Mitragotri S. Frequency dependence of sonophoresis. Pharm Res 2001;18:1694-700.
8. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci U S A 1993;90:10504-8.
9. Wang Y, Thakur R, Fan Q, Michniak B. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur J Pharm Biopharm 2005;60:179-91.
10. Singh J, Bhatia KS. Topical iontophoretic drug delivery: Pathways, principles, factors and skin irritation. Med Res Rev 1996;16:285-96.
11. Banga AK, Chien YW. Hydrogel based ionotherapeutic delivery devices for transdermal delivery of peptide/protein drugs. Pharm Res 1993;10:697-702.
12. Pikal MJ. The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv Rev 2001;46:281-305.
13. Femenía-Font A, Balaguer-Fernández C, Merino V, López-Castellano A. Combination strategies for enhancing transdermal absorption of sumatriptan through skin. Int J Pharm 2006;323:125-30.
14. Stagni G, Shukla C. Pharmacokinetics of methotrexate in rabbit skin and plasma after iv-bolus and iontophoretic administrations. J Control Release 2003;93:283-92.
15. Vaidyanathan R, Chaubal MG, Vasavada RC. Effect of pH and solubility on in vivo skin penetration of methotrexate from 50%
Prasad, et al.: Transdermal delivery of methotrexate

16. Weinstein GD, McCullough JL, Olsen E. Topical methotrexate therapy for psoriasis. Arch Dermatol 1989;125:227-30.

17. Hwang GC, Lin AY, Chen W, Sharpe RJ. Development and optimization of a methotrexate topical formulation. Drug Dev Ind Pharm 1995;21:1941-52.

18. Chatterjee DJ, Li WY, Koda RT. Effect of vehicles and penetration enhancers on in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Pharm Res 1997;14:1058-65.

19. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, van der Kerhof PC. Methotrexate revisited: Effects of long term treatment in psoriasis. Br J Dermatol 1994;130:204-10.

20. Falamarzian M, Varhosaz J. The effect of structural changes on swelling kinetics of polybasic/hidrophobic pH-sensitive hydrogels. Drug Dev Ind Pharm 1998;24:667-9.

21. Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: Iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm 2001;215:57-65.

22. Alvarez-Figueroa MJ, Delgado-Charro MB, Blanco-Mendez J. Passive and iontophoretic transdermal penetration of methotrexate. Int J Pharm 2001;212:101-7.

23. Prasad R, Koul V, Anand S. Effect of DC/m DC iontophoresis and terpenes on transdermal permeation of methotrexate: In vitro study. Int J Pharm 2007;333:70-8.

24. Tiwari SB, Kumar BCR, Udupa N, Balchandran C. Topical methotrexate delivered by iontophoresis in the treatment of recalcitrant psoriasis- a case report. Int J Dermatol 2003;42:157-9.

25. Pillai O, Panchagnula R. Transdermal Iontophoresis of Insulin VI. Influence of pretreatment with fatty acids on permeation across rat skin. Skin Pharmacol Physiol 2004;17:289-97.

26. Ingram AJ, Grasso P. Patch testing in the rabbit using a modified human patch test method. Br J Dermatol 1975;109:191-8.

27. Lashmata UR, Hadgraft J, Thomas N. Topical application of penetration enhancers to the skin of nude mice: A histopathological study. J Pharm Pharmacol 1989;41:118-22.

28. Prasad R, Anand S, Khar RK, Dinda AK, Koul V. Studies on in vitro and in vivo transdermal flux enhancement of methotrexate by a combinational approach in comparison to oral delivery. Drug Dev Ind Pharm 2009;35:1281-92.

29. Cazares-Delgadillo J, Ganem-Rondero A, Quintanar-Guerrero D, López-Castellano AC, Merino V, Kallia YN. Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: Effect of experimental conditions and a comparison with other enhancement strategies. Eur J Pharm Sci 2010;39:387-93.

30. Cullander C. What are the pathways of iontophoretic current flow through mammalian skin?. Adv Drug Del Rev 1992;9:119-35.

31. Monteiro-Riviere NA. Identification of the pathway of transdermal iontophoretic drug delivery: Ultrastructural studies using mercuric chloride in vivo in pigs. Pharm Res 1991;8:S-141.

32. Kajimoto K, Yamamoto M, Watanabe M, Kigasawa K, Kanamura K, Harashima H, et al. Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis. Int J Pharm 2011;403:57-65.

How to cite this article: Prasad R, Anand S, Koul V. Biophysical assessment of DC iontophoresis and current density on transdermal permeation of methotrexate. Int J Pharma Investig 2011;1:234-9.

Source of Support: Nil. Conflict of Interest: None declared.